Tom Brody,
Tom (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosis)) Brody
Elsevier Science
e druk, 2016
9780128042175
Clinical Trials
Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Specificaties
Gebonden, blz.
|
Engels
Elsevier Science |
e druk, 2016
ISBN13: 9780128042175
Rubricering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
Clinical Trials, Second Edition, offers those engaged in clinical trial design a valuable and practical guide. This book takes an integrated approach to incorporate biomedical science, laboratory data of human study, endpoint specification, legal and regulatory aspects and much more with the fundamentals of clinical trial design. It provides an overview of the design options along with the specific details of trial design and offers guidance on how to make appropriate choices. Full of numerous examples and now containing actual decisions from FDA reviewers to better inform trial design, the 2nd edition of Clinical Trials is a must-have resource for early and mid-career researchers and clinicians who design and conduct clinical trials.
Specificaties
Inhoudsopgave
<p>1. The Origins of Drugs<br>2. Introduction to Clinical Trial Design<br>3. Run-in Period<br>4. Inclusion/Exclusion Criteria, Stratification and Subgroups – Part I<br>5. Inclusion and Stratification Criteria – Part II<br>6. Randomization, Allocation, and Binding<br>7. Intent to Treat Analysis vs. Per Protocol Analysis<br>8. Biostatistics – Part I<br>9. Biostatistics – Part II<br>10. Introduction to Endpoints for Clinical Trials in Pharmacology<br>11. Endpoints in Clinical Trials on Solid Tumors – Objective Response<br>12. Oncology Endpoints: Overall Survival and Profession-Free Survival<br>13. Oncology Endpoints: Time to Progression<br>14. Oncology Endpoint: Disease-Free Survival<br>15. Oncology Endpoint: Time to Distant Metastasis<br>16. Neoadjuvant Therapy vs. Adjuvant Therapy<br>17. Hematological Cancers<br>18. Biomarkers and Personalized Medicine<br>19. Endpoints in Immune Diseases<br>20. Endpoints in Clinical Trials on Infections<br>21. Health-Related Quality of Life<br>22. Health-Related Quality of Life Instruments for Immune Disorders<br>23. Health-Related Quality of Life Instruments and Infections<br>24. Drug Safety<br>25. Mechanisms of Action, Part I<br>26. Mechanisms of Action, Part II – Cancer<br>27. Mechanisms of Action, Part III – Immune Disorders <br>28. Mechanisms of Action, Part IV- Infections<br>29. Consent Forms<br>30. Package Inserts<br>31. Regulatory Approval<br>32. Patents</p>